Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of EXOSOME-MSC (Mesenchymal Stem Cell-Derived Exosomes) Therapy to Reduce Hyper-inflammation In Moderate COVID-19 (2019- New Corona Virus Disease) Patients

NCT05216562 is registered in ClinicalTrials.gov with Dermama Bioteknologi Laboratorium as lead sponsor.

NCT NCT05216562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05216562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of EXOSOME-MSC (Mesenchymal Stem Cell-Derived Exosomes) Therapy to Reduce Hyper-inflammation In Moderate COVID-19 (2019- New Corona Virus Disease) Patients
Lead sponsor
Dermama Bioteknologi Laboratorium
Phase
Phase 2/3
Overall status
Unknown status
Start date
July 1, 2021
Completion date
December 30, 2022
Enrollment
60 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov2 infection